Edgestream Partners L.P. Takes $3.08 Million Position in Innoviva, Inc. $INVA

Posted by on Aug 2nd, 2026

Edgestream Partners L.P. purchased a new stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) in the first quarter, Holdings Channel reports. The firm purchased 132,225 shares of the biotechnology company’s stock, valued at approximately $3,081,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of INVA. Royal Bank of Canada grew its stake in Innoviva by 81.1% in the first quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 9,639 shares in the last quarter. AQR Capital Management LLC raised its position in Innoviva by 17.8% during the 1st quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock valued at $3,036,000 after purchasing an additional 25,317 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Innoviva by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 1,392 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Innoviva in the 1st quarter worth $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Innoviva by 21.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock worth $3,102,000 after buying an additional 30,792 shares during the period. Institutional investors own 99.12% of the company’s stock.

Innoviva Stock Down 1.2%

Innoviva stock opened at $20.97 on Friday. The company has a quick ratio of 20.07, a current ratio of 21.13 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.55 billion, a P/E ratio of 3.49 and a beta of 0.34. The business has a fifty day moving average of $22.19 and a two-hundred day moving average of $22.24. Innoviva, Inc. has a twelve month low of $16.52 and a twelve month high of $25.15.

Innoviva (NASDAQ:INVA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $97.99 million for the quarter, compared to the consensus estimate of $101.57 million. Innoviva had a return on equity of 33.33% and a net margin of 119.89%. On average, analysts forecast that Innoviva, Inc. will post 2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of Innoviva in a report on Monday, June 1st. BTIG Research reiterated a “buy” rating and set a $42.00 target price on shares of Innoviva in a report on Monday, June 22nd. Finally, Wall Street Zen downgraded shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Read Our Latest Stock Analysis on Innoviva

Innoviva Company Profile

(Free Report)

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.

Read More

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVA – Free Report).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.